# An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

> **NCT02192697** · PHASE1,PHASE2 · TERMINATED · sponsor: **Astellas Pharma Inc** · enrollment: 124 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** ASP8273

## Key facts

- **NCT ID:** NCT02192697
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-01-23
- **Primary completion:** 2016-01-15
- **Final completion:** 2017-06-14
- **Target enrollment:** 124 (ACTUAL)
- **Why stopped:** Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies.
- **Last updated:** 2024-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02192697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02192697, "An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02192697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*